## **Thomas Beyer**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6371335/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Development of anthropomorphic mathematical phantoms for simulations of clinical cases in diagnostic nuclear medicine. Computer Methods in Biomechanics and Biomedical Engineering: Imaging and Visualization, 2023, 11, 433-441.	1.9	4
2	Accuracy of PET quantification in [68Ga]Ga-pentixafor PET/MR imaging of carotid plaques. Journal of Nuclear Cardiology, 2022, 29, 492-502.	2.1	3
3	Assessment of left and right ventricular functional parameters using dynamic dual-tracer [13N]NH3 and [18F]FDG PET/MRI. Journal of Nuclear Cardiology, 2022, 29, 1003-1017.	2.1	6
4	Diagnostic Reference Levels for nuclear medicine imaging in Austria: A nationwide survey of used dose levels for adult patients. Zeitschrift Fur Medizinische Physik, 2022, 32, 283-295.	1.5	5
5	Technical note: A PET/MR coil with an integrated, orbiting 511ÂkeV transmission source for PET/MR imaging validated in an animal study. Medical Physics, 2022, 49, 2366-2372.	3.0	3
6	Implementation of a Spatially-Variant and Tissue-Dependent Positron Range Correction for PET/CT Imaging. Frontiers in Physiology, 2022, 13, 818463.	2.8	6
7	PET/MRI in the Presurgical Evaluation of Patients with Epilepsy: A Concordance Analysis. Biomedicines, 2022, 10, 949.	3.2	6
8	Evaluation of different positron range correction implementations in iterative image reconstruction for I-124 PET imaging. Nuklearmedizin - NuclearMedicine, 2022, 61, .	0.7	0
9	Additively manufactured, solid object structures for adjustable image contrast in Magnetic Resonance Imaging. Zeitschrift Fur Medizinische Physik, 2022, 32, 466-476.	1.5	0
10	Conditional Generative Adversarial Networks Aided Motion Correction of Dynamic <sup>18</sup> F-FDG PET Brain Studies. Journal of Nuclear Medicine, 2021, 62, 871-879.	5.0	26
11	Supervised machine learning enables non-invasive lesion characterization in primary prostate cancer with [68Ga]Ga-PSMA-11 PET/MRI. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1795-1805.	6.4	72
12	Potentials and caveats of AI in hybrid imaging. Methods, 2021, 188, 4-19.	3.8	12
13	Local statistical regularization method for solving image reconstruction problems in emission Tomography with Poisson data. AIP Conference Proceedings, 2021, , .	0.4	0
14	Standard MRI-based attenuation correction for PET/MRI phantoms: a novel concept using MRI-visible polymer. EJNMMI Physics, 2021, 8, 18.	2.7	8
15	Breast Tumor Characterization Using [18F]FDG-PET/CT Imaging Combined with Data Preprocessing and Radiomics. Cancers, 2021, 13, 1249.	3.7	32
16	Leadership in Medicine, Industry, and Innovation: A Conversation Between Jörg F. Debatin and Thomas Beyer. Journal of Nuclear Medicine, 2021, 62, 435-437.	5.0	0
17	Reducing Radiation Exposure to Paediatric Patients Undergoing [18F]FDG-PET/CT Imaging. Molecular Imaging and Biology, 2021, 23, 775-786.	2.6	17
18	Medical Physics and Imaging–A Timely Perspective. Frontiers in Physics, 2021, 9, .	2.1	5

#	Article	IF	CITATIONS
19	Data-driven, projection-based respiratory motion compensation of PET data for cardiac PET/CT and PET/MR imaging. Journal of Nuclear Cardiology, 2020, 27, 2216-2230.	2.1	25
20	Quantitative PET/MR imaging of lung cancer in the presence of artifacts in the MR-based attenuation correction maps. Acta Radiologica, 2020, 61, 11-20.	1.1	6
21	Advancing Biomarker Development Through Convergent Engagement: Summary Report of the 2nd International Danube Symposium on Biomarker Development, Molecular Imaging and Applied Diagnostics; March 14–16, 2018; Vienna, Austria. Molecular Imaging and Biology, 2020, 22, 47-65.	2.6	4
22	Promise of Fully Integrated PET/MRI: Noninvasive Clinical Quantification of Cerebral Glucose Metabolism. Journal of Nuclear Medicine, 2020, 61, 276-284.	5.0	15
23	PET/MRI versus PET/CT in oncology: a prospective single-center study of 330 examinations focusing on implications for patient management and cost considerations. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 51-60.	6.4	98
24	PI-RADS 2.1 – Image Interpretation: The Most Important Updates andÂTheir Clinical Implications. RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren, 2020, 193, 787-796.	1.3	5
25	What scans we will read: imaging instrumentation trends in clinical oncology. Cancer Imaging, 2020, 20, 38.	2.8	35
26	Utility of Absolute Quantification in Non-lesional Extratemporal Lobe Epilepsy Using FDG PET/MR Imaging. Frontiers in Neurology, 2020, 11, 54.	2.4	21
27	Physical imaging phantoms for simulation of tumor heterogeneity in PET, CT, and MRI: An overview of existing designs. Medical Physics, 2020, 47, 2023-2037.	3.0	44
28	Applied Systems Biology—embracing molecular imaging for systemic medicine. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2721-2725.	6.4	9
29	Lesion Detection and Administered Activity. Journal of Nuclear Medicine, 2020, 61, 1406-1410.	5.0	6
30	Fully Integrated PET/MR Imaging for the Assessment of the Relationship Between Functional Connectivity and Glucose Metabolic Rate. Frontiers in Neuroscience, 2020, 14, 252.	2.8	10
31	20 Years of PET/CT: A Conversation with David Townsend and Thomas Beyer. Journal of Nuclear Medicine, 2020, 61, 1541-1543.	5.0	4
32	Evaluation of tissue-dependent and spatially-variant positron-range correction for Iodine-124 PET/MR data. Nuklearmedizin - NuclearMedicine, 2020, 59, .	0.7	0
33	Assessment of the prompt gamma coincidence correction approach using I-124: a phantom study. , 2020, 59, .		0
34	Understanding gender pattern differences in MET-PET Glioma patients with radiomics analysis. Nuklearmedizin - NuclearMedicine, 2020, 59, .	0.7	0
35	in vivo D'Amico score for low-high risk and biochemical recurrence prediction in prostate patients with PET/MRI and machine learning. , 2020, 59, .		0
36	A simple multi-modality phantom for simulating radiomic features in PET, CT and MRI. Nuklearmedizin - NuclearMedicine, 2020, 59, .	0.7	0

#	Article	IF	CITATIONS
37	Reducing [ 18 F]FDG activity levels for whole-body PET/CT examinations of children. , 2020, 59, .		0
38	GATE Monte Carlo simulation model of the Symbia Intevo SPECT/CT system. Nuklearmedizin - NuclearMedicine, 2020, 59, .	0.7	0
39	Parameterisation of Positron Range Effects in PET/MRI. Nuklearmedizin - NuclearMedicine, 2020, 59, .	0.7	0
40	A Conversation Between Yasuhito Sasaki and Thomas Beyer. Journal of Nuclear Medicine, 2020, 61, 940-942.	5.0	0
41	Towards quantitative [18F]FDG-PET/MRI of the brain: Automated MR-driven calculation of an image-derived input function for the non-invasive determination of cerebral glucose metabolic rates. Journal of Cerebral Blood Flow and Metabolism, 2019, 39, 1516-1530.	4.3	42
42	Design, Implementation, and Evaluation of a Head and Neck MRI RF Array Integrated with a 511 keV Transmission Source for Attenuation Correction in PET/MR. Sensors, 2019, 19, 3297.	3.8	5
43	Attitudes and Knowledge Regarding Postmortem Cornea Donation among Young and Elderly People in Germany: Sufficient for Decision Making?. Ophthalmic Research, 2019, 62, 173-184.	1.9	2
44	State of affairs of hybrid imaging in Europe: two multi-national surveys from 2017. Insights Into Imaging, 2019, 10, 57.	3.4	2
45	Clinically Valuable Quality Control for PET/MRI Systems: Consensus Recommendation From the HYBRID Consortium. Frontiers in Physics, 2019, 7, .	2.1	12
46	In Patients We Trust: Reliability of Self-Reported Weight and Height in Nuclear Medicine Patients. Journal of Nuclear Medicine Technology, 2019, 47, 133-136.	0.8	6
47	European multicentre study on technical success and long-term clinical outcome of radiofrequency ablation for the treatment of spinal osteoid osteomas and osteoblastomas. Neuroradiology, 2019, 61, 935-942.	2.2	24
48	Impact of intensity discretization on textural indices of [ <sup>18</sup> F]FDG-PET tumour heterogeneity in lung cancer patients. Physics in Medicine and Biology, 2019, 64, 125016.	3.0	10
49	Preparing data for multiparametric PET/MR imaging: Influence of PET point spread function modelling and EPI distortion correction on the spatial correlation of [18F]FDG-PET and diffusion-weighted MRI in head and neck cancer. Physica Medica, 2019, 61, 1-7.	0.7	8
50	Whole-Body [18F]-FDG-PET/MRI for Oncology: A Consensus Recommendation. RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren, 2019, 191, 289-297.	1.3	15
51	Whole-Body [18F]-FDG-PET/MRI for Oncology: A Consensus Recommendation. Nuklearmedizin - NuclearMedicine, 2019, 58, 68-76.	0.7	20
52	Attenuation Correction Approaches for Serotonin Transporter Quantification With PET/MRI. Frontiers in Physiology, 2019, 10, 1422.	2.8	5
53	Optimized Feature Extraction for Radiomics Analysis of <sup>18</sup> F-FDG PET Imaging. Journal of Nuclear Medicine, 2019, 60, 864-872.	5.0	46
54	An International Survey on Clinical Reporting of PET/CT Examinations: A Starting Point for Cross-Specialty Engagement. Journal of Nuclear Medicine, 2019, 60, 480-485.	5.0	8

#	Article	IF	CITATIONS
55	Dynamic [18F]FET-PET/MRI using standard MRI-based attenuation correction methods. European Radiology, 2019, 29, 4276-4285.	4.5	8
56	Performance Evaluation of the Vereos PET/CT System According to the NEMA NU2-2012 Standard. Journal of Nuclear Medicine, 2019, 60, 561-567.	5.0	117
57	Assessment of attenuation correction for myocardial PET imaging using combined PET/MRI. Journal of Nuclear Cardiology, 2019, 26, 1107-1118.	2.1	42
58	Comparison of machine learning-driven lesion classifiers in prostate PET/MRI cases over different repeatability categories of radiomic features. , 2019, 58, .		0
59	Fuzzy Radiomics: A novel approach to minimize the effects of target delineation on radiomic models. Nuklearmedizin - NuclearMedicine, 2019, 58, .	0.7	3
60	Inter-site variability of quality control procedures and NEMA image quality in PET/MRI systems. , 2019, 58, .		0
61	Life is not black and white, nor just Shades of Gray. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 816-821.	6.4	3
62	An international survey on hybrid imaging: do technology advances preempt our training and education efforts?. Cancer Imaging, 2018, 18, 15.	2.8	11
63	Partial volume correction for improved PET quantification in 18F-NaF imaging of atherosclerotic plaques. Journal of Nuclear Cardiology, 2018, 25, 1742-1756.	2.1	29
64	Glioma Survival Prediction with Combined Analysis of In Vivo <sup>11</sup> C-MET PET Features, Ex Vivo Features, and Patient Features by Supervised Machine Learning. Journal of Nuclear Medicine, 2018, 59, 892-899.	5.0	94
65	Impact of motion compensation and partial volume correction for <sup>18</sup> F-NaF PET/CT imaging of coronary plaque. Physics in Medicine and Biology, 2018, 63, 015005.	3.0	15
66	A head coil system with an integrated orbiting transmission point source mechanism for attenuation correction in PET/MRI. Physics in Medicine and Biology, 2018, 63, 225014.	3.0	12
67	A new model for training in hybrid imaging. Lancet Oncology, The, 2018, 19, 1152-1154.	10.7	3
68	Hybrid Imaging: Instrumentation and Data Processing. Frontiers in Physics, 2018, 6, .	2.1	30
69	Personalizing Medicine Through Hybrid Imaging and Medical Big Data Analysis. Frontiers in Physics, 2018, 6, .	2.1	22
70	Association Between Osteogenesis and Inflammation During the Progression of Calcified Plaque Evaluated by <sup>18</sup> F-Fluoride and <sup>18</sup> F-FDG. Journal of Nuclear Medicine, 2017, 58, 968-974.	5.0	40
71	Technical Note: Fullyâ€automated analysis of Jaszczak phantom measurements as part of routine <scp>SPECT</scp> quality control. Medical Physics, 2017, 44, 1638-1645.	3.0	15
72	PET/MRI for Oncologic Brain Imaging: A Comparison of Standard MR-Based Attenuation Corrections with a Model-Based Approach for the Siemens mMR PET/MR System. Journal of Nuclear Medicine, 2017, 58, 1519-1525.	5.0	27

#	Article	IF	CITATIONS
73	Technical and instrumentational foundations of PET/MRI. European Journal of Radiology, 2017, 94, A3-A13.	2.6	39
74	Quantification accuracy of neuro-oncology PET data as a function of emission scan duration in PET/MR compared to PET/CT. European Journal of Radiology, 2017, 95, 257-264.	2.6	9
75	PET/MRI—knocking on the doors of the rich and famous. British Journal of Radiology, 2017, 90, 20170347.	2.2	7
76	Saving costs in cancer patient management through molecular imaging. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 2153-2157.	6.4	0
77	Reproducibility of Quantitative Brain Imaging Using a PET-Only and a Combined PET/MR System. Frontiers in Neuroscience, 2017, 11, 396.	2.8	8
78	PET/CT. Imaging in Medical Diagnosis and Therapy, 2017, , 339-368.	0.0	0
79	MR–Consistent Simultaneous Reconstruction of Attenuation and Activity for Non–TOF PET/MR. IEEE Transactions on Nuclear Science, 2016, 63, 2443-2451.	2.0	10
80	Variations in PET/MRI Operations: Results from an International Survey Among 39 Active Sites. Journal of Nuclear Medicine, 2016, 57, 2016-2021.	5.0	35
81	Radiation exposure levels of routine SPECT/CT imaging protocols. European Journal of Radiology, 2016, 85, 1627-1636.	2.6	28
82	PET and MRI: Is the Whole Greater than the Sum of Its Parts?. Cancer Research, 2016, 76, 6163-6166.	0.9	18
83	PET/CT is a cost-effective tool against cancer: synergy supersedes singularity. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1749-1752.	6.4	19
84	Investigating the state-of-the-art in whole-body MR-based attenuation correction: an intra-individual, inter-system, inventory study on three clinical PET/MR systems. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2016, 29, 75-87.	2.0	62
85	Quantitative assessment of atherosclerotic plaques on 18F-FDG PET/MRI: comparison with a PET/CT hybrid system. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1503-1512.	6.4	38
86	Reproducibility of MRI Dixon-Based Attenuation Correction in Combined PET/MR with Applications for Lean Body Mass Estimation. Journal of Nuclear Medicine, 2016, 57, 1096-1101.	5.0	18
87	Physikalisch-technische Grundlagen. , 2016, , 5-34.		1
88	Quality control for quantitative multicenter wholeâ€body PET/MR studies: A NEMA image quality phantom study with three current PET/MR systems. Medical Physics, 2015, 42, 5961-5969.	3.0	51
89	Automatic correction of dental artifacts in PET/MRI. Journal of Medical Imaging, 2015, 2, 024009.	1.5	8
90	Performance evaluation of the Biograph mCT Flow PET/CT system according to the NEMA NU2-2012 standard. EJNMMI Physics, 2015, 2, 26.	2.7	99

#	Article	IF	CITATIONS
91	Intravenous contrast-enhanced CT can be used for CT-based attenuation correction in clinical 111In-octreotide SPECT/CT. EJNMMI Physics, 2015, 2, 3.	2.7	1
92	Nuclear medicine innovations help (drive) healthcare (benefits). European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 173-175.	6.4	10
93	FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 328-354.	6.4	2,188
94	Dental artifacts in the head and neck region: implications for Dixon-based attenuation correction in PET/MR. EJNMMI Physics, 2015, 2, 8.	2.7	18
95	Combined PET/MRI: Multi-modality Multi-parametric Imaging Is Here. Molecular Imaging and Biology, 2015, 17, 595-608.	2.6	56
96	Simultaneous reconstruction of attenuation and activity for non–TOF PET/MR using MR prior information. EJNMMI Physics, 2015, 2, A30.	2.7	1
97	Correction of dental artifacts within the anatomical surface in PET/MRI using active shape models and k-nearest-neighbors. Proceedings of SPIE, 2014, , .	0.8	1
98	Impact of incorrect tissue classification in Dixon-based MR-AC: fat-water tissue inversion. EJNMMI Physics, 2014, 1, 101.	2.7	42
99	Combined PET/MR imaging in neurology: MR-based attenuation correction implies a strong spatial bias when ignoring bone. Neurolmage, 2014, 84, 206-216.	4.2	170
100	Whole-body PET/MRI: The effect of bone attenuation during MR-based attenuation correction in oncology imaging. European Journal of Radiology, 2014, 83, 1177-1183.	2.6	65
101	EJNMMI Physics—Access is open for open access. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 197-198.	6.4	2
102	Geometric distortions of diffusion weighted imaging of the head/neck in combined PET/MR: optimization of image acquisition and post-processing correction for oncology applications. EJNMMI Physics, 2014, 1, A76.	2.7	3
103	State-of-the-art SPECT/CT: technology, methodology and applications—defining a new role for an undervalued multimodality imaging technique. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 1-2.	6.4	14
104	EJNMMI Physics - an editor's perspective. EJNMMI Physics, 2014, 1, 1.	2.7	15
105	Combined PET/MR: Where Are We Now? Summary Report of the Second International Workshop on PET/MR Imaging April 8–12, 2013, Tubingen, Germany. Molecular Imaging and Biology, 2014, 16, 295-310.	2.6	38
106	Image Distortions in Clinical PET/MR Imaging. , 2014, , 21-41.		5
107	Variation of system performance, quality control standards and adherence to international FDG-PET/CT imaging guidelines. Nuklearmedizin - NuclearMedicine, 2014, 53, 242-248.	0.7	31
108	PET/MR imaging of the pelvis in the presence of endoprostheses: reducing image artifacts and increasing accuracy through inpainting. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 594-601.	6.4	42

#	Article	IF	CITATIONS
109	Image artifacts from MR-based attenuation correction in clinical, whole-body PET/MRI. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2013, 26, 173-181.	2.0	119
110	Clinical evaluation of PET image reconstruction using a spatial resolution model. European Journal of Radiology, 2013, 82, 862-869.	2.6	55
111	Nuclear medicine 2013: from status quo to status go. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 1794-1796.	6.4	3
112	Combined PET/CT for IMRT treatment planning of NSCLC: Contrast-enhanced CT images for Monte Carlo dose calculation. Physica Medica, 2013, 29, 644-649.	0.7	6
113	MR/PET or PET/MRI: does it matter?. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2013, 26, 1-4.	2.0	11
114	Combined PET/MR Imaging Using 68Ga-DOTATOC for Radiotherapy Treatment Planning in Meningioma Patients. Recent Results in Cancer Research, 2013, 194, 425-439.	1.8	28
115	Effect of a tail piece cysteine deletion on biochemical and functional properties of an epidermal growth factor receptor-directed IgA2 m(1) antibody. MAbs, 2013, 5, 936-945.	5.2	16
116	PET/MR Instrumentation., 2013,, 7-28.		0
117	Evaluation of PET image quality and distortions in simultaneous clinical PET/MR. , 2012, , .		1
118	Characterization of a Mutated IgA2 Antibody of the m(1) Allotype against the Epidermal Growth Factor Receptor for the Recruitment of Monocytes and Macrophages. Journal of Biological Chemistry, 2012, 287, 25139-25150.	3.4	44
119	Integration of FDG- PET/CT into external beam radiation therapy planning. Nuklearmedizin - NuclearMedicine, 2012, 51, 140-153.	0.7	52
120	MR-based Attenuation Correction for PET/MR. Series in Medical Physics and Biomedical Engineering, 2012, , 217-239.	0.1	0
121	Effect of MR contrast agents on quantitative accuracy of PET in combined whole-body PET/MR imaging. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 1756-1766.	6.4	31
122	Variations of clinical SPECT/CT operations. Nuklearmedizin - NuclearMedicine, 2012, 51, 154-160.	0.7	12
123	Multiphase contrast-enhanced CT with highly concentrated contrast agent can be used for PET attenuation correction in integrated PET/CT imaging. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 316-325.	6.4	26
124	The effect of MR surface coils on PET quantification in whole-body PET/MR: Results from a pseudo-PET/MR phantom study. Medical Physics, 2011, 38, 2795-2805.	3.0	76
125	MRI-Based Attenuation Correction for Whole-Body PET/MRI: Quantitative Evaluation of Segmentation- and Atlas-Based Methods. Journal of Nuclear Medicine, 2011, 52, 1392-1399.	5.0	255
126	Variations in Clinical PET/CT Operations: Results of an International Survey of Active PET/CT Users. Journal of Nuclear Medicine, 2011, 52, 303-310.	5.0	119

#	Article	IF	CITATIONS
127	The effect of patient positioning aids on PET quantification in PET/MR imaging. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 920-929.	6.4	35
128	Whole-body hybrid PET/MRI: ready for clinical use?. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 992-995.	6.4	53
129	The future of hybrid imaging—part 1: hybrid imaging technologies and SPECT/CT. Insights Into Imaging, 2011, 2, 161-169.	3.4	43
130	The future of hybrid imaging—part 2: PET/CT. Insights Into Imaging, 2011, 2, 225-234.	3.4	51
131	The future of hybrid imaging—part 3: PET/MR, small-animal imaging and beyond. Insights Into Imaging, 2011, 2, 235-246.	3.4	53
132	Simultaneous 68Ca-DOTATOC-PET/MRI for IMRT Treatment Planning for Meningioma: First Experience. International Journal of Radiation Oncology Biology Physics, 2011, 81, 277-283.	0.8	75
133	Subjective Perception of Radiation Risk. Journal of Nuclear Medicine, 2011, 52, 29S-35S.	5.0	49
134	Recombinant Dimeric IgA Antibodies against the Epidermal Growth Factor Receptor Mediate Effective Tumor Cell Killing. Journal of Immunology, 2011, 186, 3770-3778.	0.8	62
135	Physik/Technik. , 2011, , 7-34.		Ο
136	FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 181-200.	6.4	1,147
137	PET/CT for the assessment and quantification of 90Y biodistribution after selective internal radiotherapy (SIRT) of liver metastases. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 407-408.	6.4	50
138	High throughput static and dynamic small animal imaging using clinical PET/CT: potential preclinical applications. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 991-1001.	6.4	34
139	Is conflict of interest in our best interest?. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 1063-1068.	6.4	4
140	Time-of-flight PET/CT using low-activity protocols: potential implications for cancer therapy monitoring. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 1643-1653.	6.4	51
141	Human IgG2 Antibodies against Epidermal Growth Factor Receptor Effectively Trigger Antibody-Dependent Cellular Cytotoxicity but, in Contrast to IgG1, Only by Cells of Myeloid Lineage. Journal of Immunology, 2010, 184, 512-520.	0.8	219
142	PET Versus PET/CT Dual-Modality Imaging in Evaluation of Lung Cancer. Thoracic Surgery Clinics, 2010, 20, 25-30.	1.0	15
143	Dual-modality PET/CT instrumentation—Today and tomorrow. European Journal of Radiology, 2010, 73, 452-460.	2.6	45
144	Serum-free production and purification of chimeric IgA antibodies. Journal of Immunological Methods, 2009, 346, 26-37.	1.4	47

#	Article	IF	CITATIONS
145	Towards quantitative PET/MRI: a review of MR-based attenuation correction techniques. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 93-104.	6.4	314
146	A decade of combined imaging: from a PET attached to a CT to a PET inside an MR. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 1-2.	6.4	56
147	Diagnostic accuracy of contrast-enhanced FDG-PET/CT in primary staging of cutaneous malignant melanoma. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 910-918.	6.4	59
148	MR-based attenuation correction for torso-PET/MR imaging: pitfalls in mapping MR to CT data. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 1142-1146.	6.4	98
149	Whole-body PET/CT imaging: Combining software- and hardware-based co-registration. Zeitschrift Fur Medizinische Physik, 2008, 18, 59-66.	1.5	21
150	Multi-modality imaging of uveal melanomas using combined PET/CT, high-resolution PET and MR imaging. Nuklearmedizin - NuclearMedicine, 2008, 47, 73-9.	0.7	4
151	Effector Mechanisms of Recombinant IgA Antibodies against Epidermal Growth Factor Receptor. Journal of Immunology, 2007, 179, 2936-2943.	0.8	91
152	PET Versus PET/CT Dual-Modality Imaging in Evaluation of Lung Cancer. Radiologic Clinics of North America, 2007, 45, 639-644.	1.8	26
153	TNM staging with FDG-PET/CT in patients with primary head and neck cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2007, 34, 1953-1962.	6.4	70
154	PET Versus PET/CT Dual-Modality Imaging in Evaluation of Lung Cancer. PET Clinics, 2006, 1, 347-352.	3.0	1
155	Putting â€~clear' into nuclear medicine: a decade of PET/CT development. European Journal of Nuclear Medicine and Molecular Imaging, 2006, 33, 857-861.	6.4	40
156	Whole-body 18F-FDG PET/CT in the presence of truncation artifacts. Journal of Nuclear Medicine, 2006, 47, 91-9.	5.0	54
157	Optimized contrast-enhanced CT protocols for diagnostic whole-body 18F-FDG PET/CT: technical aspects of single-phase versus multiphase CT imaging. Journal of Nuclear Medicine, 2006, 47, 470-6.	5.0	43
158	Combined 18F-FDG-PET/CT imaging of the head and neck. An approach to metal artifact correction. Nuklearmedizin - NuclearMedicine, 2006, 45, 219-22.	0.7	8
159	Anato-Molecular Imaging: Combining Structure and Function. , 2005, , 179-202.		1
160	Respiration artifacts in whole-body 18F-FDG PET/CT studies with combined PET/CT tomographs employing spiral CT technology with 1 to 16 detector rows. European Journal of Nuclear Medicine and Molecular Imaging, 2005, 32, 1429-1439.	6.4	56
161	Contrast-Enhanced Dark Lumen PET/CT and MR Colonography in a Rodent Polyp Model: Initial Results with Histopathologic Correlation. American Journal of Roentgenology, 2005, 185, 1045-1047.	2.2	7
162	Optimized intravenous contrast administration for diagnostic whole-body 18F-FDG PET/CT. Journal of Nuclear Medicine, 2005, 46, 429-35.	5.0	60

#	Article	IF	CITATIONS
163	On the use of positioning aids to reduce misregistration in the head and neck in whole-body PET/CT studies. Journal of Nuclear Medicine, 2005, 46, 596-602.	5.0	40
164	Radiation exposure of patients undergoing whole-body dual-modality 18F-FDG PET/CT examinations. Journal of Nuclear Medicine, 2005, 46, 608-13.	5.0	298
165	1 + 1 = 3. Nuklearmedizin - NuclearMedicine, 2005, 44 Suppl 1, S1.	0.7	1
166	Towards truly integrated hardware fusion with PET/CT. Nuklearmedizin - NuclearMedicine, 2005, 44 Suppl 1, S5-12.	0.7	2
167	FDG-PET/CT in re-staging of patients with lymphoma. European Journal of Nuclear Medicine and Molecular Imaging, 2004, 31, 325-329.	6.4	226
168	Accuracy of Whole-Body Dual-Modality Fluorine-18–2-Fluoro-2-Deoxy- <scp>d</scp> -Glucose Positron Emission Tomography and Computed Tomography (FDG-PET/CT) for Tumor Staging in Solid Tumors: Comparison With CT and PET. Journal of Clinical Oncology, 2004, 22, 4357-4368.	1.6	424
169	Dual-Modality PET/CT Scanning with Negative Oral Contrast Agent to Avoid Artifacts: Introduction and Evaluation. Radiology, 2004, 230, 879-885.	7.3	141
170	Positron emission tomography/computed tomography?imaging protocols, artifacts, and pitfalls. Molecular Imaging and Biology, 2004, 6, 188-199.	2.6	125
171	Dual-Modality PET/CT Acquisition Systems for Clinical Oncology. , 2004, , 9-28.		2
172	Acquisition protocol considerations for combined PET/CT imaging. Journal of Nuclear Medicine, 2004, 45 Suppl 1, 25S-35S.	5.0	56
173	To enhance or not to enhance? 18F-FDG and CT contrast agents in dual-modality 18F-FDG PET/CT. Journal of Nuclear Medicine, 2004, 45 Suppl 1, 56S-65S.	5.0	66
174	Improving perceptions of the quality of service in nuclear medicine. European Journal of Nuclear Medicine and Molecular Imaging, 2003, 30, 472-472.	6.4	5
175	Dual-modality PET/CT imaging: the effect of respiratory motion on combined image quality in clinical oncology. European Journal of Nuclear Medicine and Molecular Imaging, 2003, 30, 588-596.	6.4	274
176	X-ray-based attenuation correction for positron emission tomography/computed tomography scanners. Seminars in Nuclear Medicine, 2003, 33, 166-179.	4.6	448
177	PET/CT scanners: A hardware approach to image fusion. Seminars in Nuclear Medicine, 2003, 33, 193-204.	4.6	224
178	Non–Small Cell Lung Cancer: Dual-Modality PET/CT in Preoperative Staging. Radiology, 2003, 229, 526-533.	7.3	525
179	Clinically feasible reconstruction of 3D whole-body PET/CT data using blurred anatomical labels. Physics in Medicine and Biology, 2002, 47, 1-20.	3.0	208
180	A combined PET/CT scanner: the path to true image fusion. British Journal of Radiology, 2002, 75, S24-S30.	2.2	197

#	Article	IF	CITATIONS
181	Image Analysis in Patients with Cancer Studied with a Combined PET and CT Scanner. Clinical Nuclear Medicine, 2000, 25, 905-910.	1.3	142
182	Combined PET/CT imaging using a single, dual-modality tomograph: a promising approach to clinical oncology of the future. , 2000, , 101-123.		12
183	A combined PET/CT scanner for clinical oncology. Journal of Nuclear Medicine, 2000, 41, 1369-79.	5.0	1,022
184	The ECAT ART Scanner for Positron Emission Tomography 2. Research and Clinical Applications. Molecular Imaging and Biology, 1999, 2, 17-30.	0.3	9
185	The ECAT ART Scanner for Positron Emission Tomography 1. Improvements in Performance Characteristics. Molecular Imaging and Biology, 1999, 2, 5-15.	0.3	24
186	Attenuation correction for a combined 3D PET/CT scanner. Medical Physics, 1998, 25, 2046-2053.	3.0	766
187	The use of X-ray CT for attenuation correction of PET data. , 0, , .		20
188	Reconstruction of 3D whole-body PET data using blurred anatomical labels. , 0, , .		0
189	The SMART scanner: a combined PET/CT tomograph for clinical oncology. , 0, , .		53